

SAFETY DATA SHEET



Version 2.4	Revision Date: 2025/08/23	SDS Number: 100000009885	Date of last issue: 2025/06/06 Date of first issue: 2013/12/23
----------------	------------------------------	-----------------------------	---

SECTION 1. IDENTIFICATION

Substance name : TREMFYA® (guselkumab) injection, for subcutaneous use (Drug product)
TREMFYA® PEN (guselkumab) injection, for subcutaneous use
100 mg/mL in a single-dose One-Press patient-controlled injector
100 mg/mL in a single-dose prefilled pen (TREMFYA PEN)
200 mg/2 mL in a single-dose prefilled pen (TREMFYA PEN)
100 mg/mL in a single-dose prefilled syringe
200 mg/2 mL in a single-dose prefilled syringe
45 mg/0.45 mL in a single-dose prefilled pen (VarioJect pen)

Reference number : JNJ-54160366-AAA

Manufacturer or supplier's details

Company name of supplier : Janssen Pharmaceuticals, Inc.

Address : 1125 Trenton-Harbourton Rd
Titusville NJ 08560

USA

Telephone : +16097302000

E-mail address of person responsible for the SDS : SDSJanssen@its.jnj.com

Emergency telephone number : **CHEMTREC US: 1-800-424-9300**
CHEMTREC International: +1 703-741-5970

Recommended use of the chemical and restrictions on use

Recommended use : Large Molecule Pharmaceutical intended for medical use.
Monoclonal antibody

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Not a hazardous substance or mixture.

GHS label elements

Not a hazardous substance or mixture.

SAFETY DATA SHEET



Version 2.4	Revision Date: 2025/08/23	SDS Number: 100000009885	Date of last issue: 2025/06/06 Date of first issue: 2013/12/23
----------------	------------------------------	-----------------------------	---

Other hazards

Immune system effects

Hypersensitivity

Long term or large scale exposure of this drug may lead to general immunosuppression.

Individuals who are at high risk (e.g. HIV-positive individuals, immunocompromised individuals) need to take precautions to minimize exposure.

Accidental injection may cause effects similar to those seen in clinical use and mentioned in the patient packaging insert.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Chemical nature : Liquid

Components

Chemical name	CAS-No.	Concentration (% w/w)
CNTO 1959	1350289-85-8	≥ 10 - < 20
alpha-D-Glucopyranoside, beta-D-fructofuranosyl	57-50-1	≥ 5 - < 10
POLYSORBATE 80#	9005-65-6	< 0.1

Voluntarily-disclosed non-hazardous substance

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

- General advice : This material is being evaluated for use as a biological agent or in the manufacturing of a biological agent.
If accidentally injected (needle prick or through broken skin):
Stimulate bleeding for approximately 5 minutes.
Wash off immediately with soap and plenty of water.
Call a physician immediately.
- If inhaled : If breathed in, move person into fresh air.
Rinse nose and mouth with salt water.
Call a physician immediately.
- In case of skin contact : Take off contaminated clothing and shoes immediately.
Wash off immediately with soap and plenty of water.
If skin irritation persists, call a physician.
Consult a physician.
Process contaminated clothing and PPE's according to hospital procedures in accordance with applicable waste disposal regulations.
- In case of eye contact : Remove contact lenses.
Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes.
Call a physician immediately.

SAFETY DATA SHEET



Version 2.4	Revision Date: 2025/08/23	SDS Number: 100000009885	Date of last issue: 2025/06/06 Date of first issue: 2013/12/23
----------------	------------------------------	-----------------------------	---

If swallowed	: Do NOT induce vomiting. If swallowed, rinse mouth with water (only if the person is conscious). Drink plenty of water. Call a physician immediately.
Most important symptoms and effects, both acute and delayed	: High risk on infections Headache Respiratory tract infections Stomach/intestinal disorders Musculoskeletal disorders Liver disorders
Notes to physician	: Treat symptomatically. Consult the patient packaging insert for more information about this Finished Pharmaceutical Product.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Water mist Foam Carbon dioxide (CO ₂) Sand Aqueous film forming foam (AFFF).
Specific hazards during firefighting	: The product is not flammable.
Hazardous combustion products	: Carbon oxides Nitrogen oxides (NO _x) Sulphur oxides
Further information	: In the event of fire, cool tanks with water spray.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Firefighters must wear fire resistant personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: In the event of an accidental release the emergency response team must respond based on a risk assessment and use personal protective equipment as appropriate. Avoid direct contact with broken glass, plastic and other sharps. Avoid formation of aerosol. Avoid splashes and spray formation. Evacuate personnel to safe areas. Avoid direct contact and significant aerosol exposure.
---	---

SAFETY DATA SHEET



Version 2.4	Revision Date: 2025/08/23	SDS Number: 100000009885	Date of last issue: 2025/06/06 Date of first issue: 2013/12/23
----------------	------------------------------	-----------------------------	---

- Environmental precautions : Should not be released into the environment.
Do not flush into surface water or sanitary sewer system.
- Methods and materials for containment and cleaning up : Small spills: Gently cover the spill with an absorbent towel or pad.
Wet absorbent pad with 10% bleach solution. Allow 30 minutes contact time.
Large spills: Allow the dust/aerosol to settle for 30 minutes or use appropriate respiratory protection.
Dam up.
Soak up with inert absorbent material.
Add bleach (5.25% sodium hypochlorite) solution to a final liquid concentration of 10% (1 part bleach, mixed with 9 parts liquid) to absorbent materials. Allow 30 minute contact time.
Large spills + Small spills: Keep in suitable, closed containers for disposal. Treat recovered material as described in the section "Disposal considerations".
Special consideration may need to be evaluated based on specific hazards.
Clean up with a 10% bleach (5.25% sodium hypochlorite) solution, 1 part bleach, mixed with 9 parts water is recommended for cleaning of surfaces and equipment.
Clean spill location and adjacent surfaces thoroughly with ethanol or water with detergent.

SECTION 7. HANDLING AND STORAGE

- Advice on protection against fire and explosion : The product is not flammable.
Take measures to prevent the build up of electrostatic charge.
- Advice on safe handling : Avoid splashes.
Avoid formation of aerosol.
Prevent exposure to aerosols and splashes.
Do not heat the product.
Avoid inhalation, ingestion and contact with skin and eyes.
- Conditions for safe storage : To maintain product quality, do not store in heat or direct sunlight.
Store in original container.
Keep containers tightly closed in a dry, cool and well-ventilated place.
Keep refrigerated.
- Recommended storage temperature : 36 - 46 °F / 2 - 8 °C

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type	Control	Basis
------------	---------	------------	---------	-------

SAFETY DATA SHEET



Version 2.4	Revision Date: 2025/08/23	SDS Number: 100000009885	Date of last issue: 2025/06/06 Date of first issue: 2013/12/23
----------------	------------------------------	-----------------------------	---

		(Form of exposure)	parameters / Permissible concentration	
CNTO 1959	1350289-85-8	PBOEL-HHC	2	J&J PBOEL-HHC list
Further information: J&J has a hazard banding notation: PBOEL HHC. This substance is classified by J&J as being PBOEL HHC 2. This means that the OEL is estimated to be from 20 to 100 µg/m3				
alpha-D-Glucopyranoside, beta-D-fructofuranosyl	57-50-1	TWA	10 mg/m3	ACGIH
		TWA (Respirable)	5 mg/m3	NIOSH REL
		TWA (total)	10 mg/m3	NIOSH REL
		TWA (total dust)	15 mg/m3	OSHA Z-1
		TWA (respirable fraction)	5 mg/m3	OSHA Z-1
		TWA (Total dust)	15 mg/m3	OSHA P0
		TWA (respirable dust fraction)	5 mg/m3	OSHA P0

Engineering measures : All personal protective equipment should be based on a risk assessment. Consult a Environment Health Safety expert if necessary.

Personal protective equipment

Respiratory protection : Engineering controls should always be the primary method of controlling exposures.
There is remote possibility that this product could be aerosolized and inhaled in the workplace.
If respiratory protective equipment is needed for certain activities, the type as well as the corresponding protection factor will depend upon the risk assessment and air concentrations, hazards, physical and warning properties of substances present.
No personal respiratory protective equipment normally required.

Hand protection
Remarks : Disposable gloves

Eye protection : Safety glasses

Skin and body protection : Lab coat

Protective measures : The type of protective equipment must be selected based on the Environmental Health and Safety risk assessment.
Consult a Environmental Health and Safety expert if necessary.

SAFETY DATA SHEET



Version 2.4	Revision Date: 2025/08/23	SDS Number: 100000009885	Date of last issue: 2025/06/06 Date of first issue: 2013/12/23
----------------	------------------------------	-----------------------------	---

Hygiene measures : Handle in accordance with good industrial hygiene and safety practice.
Remove gloves and wash hands when work with material is completed. Do not reuse gloves.
In some cases, wearing two pairs of gloves may be appropriate.
Contaminated work clothing should not be allowed out of the workplace.
Avoid use of sharps, utilize safe-engineered sharps or non-penetrable gloves, where appropriate.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: Aqueous solution, Prefilled syringe
Colour	: clear, colourless, to, light yellow
Odour	: No data available
pH	: 5.8
Melting point/freezing point	: No data available
Boiling point/boiling range	: No data available
Flash point	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: No data available
Relative vapour density	: No data available
Density	: No data available
Solubility(ies)	
<u>Solubility in other solvents</u>	: No data available
Partition coefficient: n-octanol/water	: No data available
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
<u>Viscosity, kinematic</u>	: No data available

SAFETY DATA SHEET



Version 2.4	Revision Date: 2025/08/23	SDS Number: 100000009885	Date of last issue: 2025/06/06 Date of first issue: 2013/12/23
----------------	------------------------------	-----------------------------	---

SECTION 10. STABILITY AND REACTIVITY

Reactivity	: None reasonably foreseeable.
Chemical stability	: Stable under recommended storage conditions.
Possibility of hazardous reactions	: No dangerous reaction known under conditions of normal use.
Conditions to avoid	: To avoid thermal decomposition, do not overheat. Exposure to light.
Incompatible materials	: Oxidizing agents Peroxides, organic Chlorine-based bleaching agents
Hazardous decomposition products	: Halogenated compounds

SECTION 11. TOXICOLOGICAL INFORMATION

Acute toxicity

Product:

Acute oral toxicity	: Remarks: Single-dose acute toxicity studies were not performed. This product is a large protein biotherapeutic intended for injection. It is not expected to be absorbed via the oral, dermal, or inhalation routes of exposure.
Acute inhalation toxicity	: Remarks: Single-dose acute toxicity studies were not performed. This product is a large protein biotherapeutic intended for injection. It is not expected to be absorbed via the oral, dermal, or inhalation routes of exposure.
Acute dermal toxicity	: Remarks: Single-dose acute toxicity studies were not performed. This product is a large protein biotherapeutic intended for injection. It is not expected to be absorbed via the oral, dermal, or inhalation routes of exposure.
Acute toxicity (other routes of administration)	: Acute toxicity estimate (Monkey, male): 50 mg/kg Application Route: intravenous injection GLP: no Remarks: No animal death. Acute toxicity estimate (Monkey, male): 1 mg/kg Application Route: Subcutaneous; injection made in the back or neck of animal GLP: no Remarks: No animal death.

SAFETY DATA SHEET



Version 2.4	Revision Date: 2025/08/23	SDS Number: 100000009885	Date of last issue: 2025/06/06 Date of first issue: 2013/12/23
----------------	------------------------------	-----------------------------	---

Acute toxicity estimate (Monkey, male): 10 mg/kg
Application Route: Subcutaneous; injection made in the back or neck of animal
GLP: no
Remarks: No animal death.

Acute toxicity estimate (Monkey, male): 50 mg/kg
Application Route: Subcutaneous; injection made in the back or neck of animal
GLP: no
Remarks: No animal death.

Remarks: This product is not expected to be absorbed via the oral, dermal, or inhalation routes of exposure.

Components:

POLYSORBATE 80:

Acute toxicity (other routes of administration) : LD50 (Rat): 6,804 mg/kg
Application Route: oral administration

Skin corrosion/irritation

Product:

Remarks : Large protein biotherapeutics in the dry or reconstituted (solution in buffer) forms are not expected to elicit skin corrosion/irritation, skin sensitization, or cause damage to/irritate the eyes.

Serious eye damage/eye irritation

Product:

Remarks : Large protein biotherapeutics in the dry or reconstituted (solution in buffer) forms are not expected to elicit skin corrosion/irritation, skin sensitization, or cause damage to/irritate the eyes.

Respiratory or skin sensitisation

Product:

Remarks : Large protein biotherapeutics in the dry or reconstituted (solution in buffer) forms are not expected to elicit skin corrosion/irritation, skin sensitization, or cause damage to/irritate the eyes.

Germ cell mutagenicity

Product:

Germ cell mutagenicity - : Routine genotoxicity studies are not applicable to

SAFETY DATA SHEET



Version 2.4	Revision Date: 2025/08/23	SDS Number: 100000009885	Date of last issue: 2025/06/06 Date of first issue: 2013/12/23
----------------	------------------------------	-----------------------------	---

Assessment biotherapeutics as large proteins cannot diffuse into cells and interact with DNA or chromosomal material.

Carcinogenicity

Product:

Carcinogenicity - Assessment : Standard carcinogenicity bioassays are generally inappropriate for biotechnology derived pharmaceuticals.

The risk of malignancy is low based on weight of evidence, but it cannot be excluded as a potential hazard.

IARC No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Product:

Effects on fertility : Species: Guinea pig, male
Application Route: Subcutaneous; injection made in the back or neck of animal
Dose: 25, 100mg/kg
Frequency of Treatment: 2 days/week
General Toxicity - Parent: NOAEL: 100 mg/kg
GLP: yes
Remarks: No adverse effects on sexual function and fertility.

Species: Guinea pig, female
Application Route: Subcutaneous; injection made in the back or neck of animal
Dose: 0, 25, 100mg/kg
Frequency of Treatment: 2 days/week
General Toxicity - Parent: NOAEL: 100 mg/kg
GLP: yes
Remarks: No adverse effects on sexual function and fertility.

Species: Monkey, male and female
Application Route: Subcutaneous; injection made in the back or neck of animal
Dose: 10, 50mg/kg
Frequency of Treatment: 1 days/week
General Toxicity - Parent: NOAEL: 50 mg/kg
GLP: yes
Remarks: No effect on fertility endpoints was observed in non-human primates.

SAFETY DATA SHEET



Version 2.4	Revision Date: 2025/08/23	SDS Number: 100000009885	Date of last issue: 2025/06/06 Date of first issue: 2013/12/23
----------------	------------------------------	-----------------------------	---

Effects on foetal development : Remarks: Generally, juvenile toxicology studies are not conducted for this product.

Reproductive toxicity - Assessment : As an IgG1 monoclonal antibody, it may be transferred across the placenta.

Teratogenicity - Assessment : Did not show teratogenic effects in animal experiments.

No effects on or via lactation

STOT - single exposure

Product:

Remarks : No data available

STOT - repeated exposure

Product:

Exposure routes : Subcutaneous; injection made in the back or neck of animal

Target Organs : No specific target organs noted

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Remarks : No significant adverse effects were reported

Exposure routes : intravenous injection

Target Organs : No specific target organs noted

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Remarks : No significant adverse effects were reported

Repeated dose toxicity

Product:

Species : Non-human primate, male and female

NOAEL : 50 mg/kg

Application Route : Subcutaneous; injection made in the back or neck of animal

Exposure time : 5 weeks, 24 weeks

Number of exposures : 1 x week

Dose : 0, 10, 50mg/kg

Subsequent observation period : 3-month recovery

GLP : yes

Remarks : No significant adverse effects were reported

Species : Non-human primate, male and female

NOAEL : 50 mg/kg

Application Route : intravenous injection

Exposure time : 5 weeks

Number of exposures : 1 x week

Dose : 0, 50mg/kg

GLP : yes

Remarks : No significant adverse effects were reported

SAFETY DATA SHEET



Version 2.4	Revision Date: 2025/08/23	SDS Number: 100000009885	Date of last issue: 2025/06/06 Date of first issue: 2013/12/23
----------------	------------------------------	-----------------------------	---

Aspiration toxicity

Product:

No data available

Experience with human exposure

No data available

Toxicology, Metabolism, Distribution

No data available

Neurological effects

No data available

Further information

Product:

Remarks : No immunotoxicity effects were observed.

Other health hazards

No data available

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

No data available

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : In accordance with National, Federal, State and Local regulations.
Decontaminate all waste (i.e. steam sterilization/autoclaving, chemical disinfection) before disposal or ensure incineration of medical waste as a proper disposal route

SAFETY DATA SHEET



Version 2.4	Revision Date: 2025/08/23	SDS Number: 100000009885	Date of last issue: 2025/06/06 Date of first issue: 2013/12/23
----------------	------------------------------	-----------------------------	---

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

49 CFR

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Massachusetts Right To Know

alpha-D-Glucopyranoside, beta-D-fructofuranosyl	57-50-1
---	---------

Pennsylvania Right To Know

water	7732-18-5
CNTO 1959	1350289-85-8
alpha-D-Glucopyranoside, beta-D-fructofuranosyl	57-50-1

New Jersey Right To Know

water	7732-18-5
CNTO 1959	1350289-85-8
alpha-D-Glucopyranoside, beta-D-fructofuranosyl	57-50-1

New York City Hazardous Substances

No components listed on the New York City Hazardous Substances List

California Prop. 65

This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

Version	Revision Date:	SDS Number:	Date of last issue: 2025/06/06
2.4	2025/08/23	100000009885	Date of first issue: 2013/12/23

California Permissible Exposure Limits for Chemical Contaminants

alpha-D-Glucopyranoside, beta-D-fructofuranosyl 57-50-1

Other regulations

Restricted to professional users.

Biosafety Regulations and Guidelines:

World Health Organization, Laboratory biosafety manual. - 4 th ed., ISBN 9789240011311, 2020, pp. 124.

OSHA Bloodborne Pathogen Standard 29 CFR 1910.1030 and the OSHA Standard

Interpretation on Applicability of 1910.1030 to Establish Human Cell Lines;

U.S. Department of Health and Human Services Public Health Services, Biosafety in Microbiological and Biomedical Laboratories (BMBL) - 5th ed., HHS Publication No. (CDC) 21-1112

SECTION 16. OTHER INFORMATION**Full text of other abbreviations**

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA P0	:	USA. Table Z-1-A Limits for Air Contaminants (1989 vacated values)
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA P0 / TWA	:	8-hour time weighted average
OSHA Z-1 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect

SAFETY DATA SHEET



Version 2.4	Revision Date: 2025/08/23	SDS Number: 100000009885	Date of last issue: 2025/06/06 Date of first issue: 2013/12/23
----------------	------------------------------	-----------------------------	---

Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 2025/08/23

Date and Number Formats

This document uses the following notation for printing dates and numbers:

Date:	Dec 31th, 2012	as	2012/12/31
Numbers:	123456,78	as	123,456.78

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN